Skip to main content
. 2022 Apr 19;13:832215. doi: 10.3389/fphar.2022.832215

TABLE 2.

Summary of simulation results.

Analysis Incremental ICER, $/QALY
Cost, $ QALYs Cost, $ QALYs
Base case analysis
 First-line chemotherapy 22,943 1.63
 First-line LY01008 combined with chemotherapy 49,182 2.11 26,240 0.48 54,430
Scenario analysis
 First-line chemotherapy 22,943 1.63
 First-line LY01008 combined with chemotherapy 38,429 2.11 15,487 0.48 32,125

QALYs, quality-adjusted life-years; ICER, incremental cost-effectiveness ratio.